Johnson & Johnson has announced the completion of the acquisition of Ci:z Holdings Co., Ltd. for a total purchase price of approximately 230 billion Japanese Yen. The acquisition expands J&J’s portfolio of science-based dermocosmetic beauty products.

Johnson & Johnson plans to acquire the remaining shares of the company that were not tendered in the tender offer through a share consolidation under Japanese law, during the first half of 2019 — and take appropriate actions to delist the company from the Tokyo Stock Exchange.

 Ci:z Holdings Co. markets the DR. CI:LABO, LABO LABO and GENOMER skincare lines. They will now become part of the Johnson & Johnson Family of Consumer Companies.

“This addition to our franchise strengthens our growing beauty portfolio with unique dermocosmetic innovation,” said Jorge Mesquita, Worldwide Chairman, Johnson & Johnson Consumer. “We are very pleased to complete this important transaction and look forward to bringing efficacious, science-backed skincare products to our health and beauty consumers around the world.”

Any EPS impact of the transaction will be included in the 2019 guidance provided on Johnson & Johnson’s Q4 2018 earnings call.